Navigation Links
Quanticel Pharmaceuticals Enters Into Strategic Cancer Drug Discovery Collaboration With Celgene Corporation
Date:11/4/2011

and protein regulation. For more information, please visit the Company's website at www.celgene.com.

About Versant Ventures

Versant Ventures is a leading healthcare-focused venture capital firm specializing in seed, early-stage and selective later-stage investments in medical devices, biotechnology and pharmaceuticals. Founded in 1999, Versant has a world-class capability for startup incubation. The firm engineers innovative business models to create value and a path toward liquidity, and partners with both entrepreneurs and pharmaceutical companies to facilitate transactions. Several examples of the unique model in addition to Quanticel include Amira, Synosia, Flexion, Kythera, and Inception. Versant Ventures has a seasoned team of 13 managing directors with more than 170 years of venture capital investing experience and approximately 145 years of operating experience. The firm currently has more than $1.6 billion in capital and works with 95 companies in its portfolios. Versant has three offices in California in Silicon Valley, Orange County and San Francisco. For more information, please visit www.versantventures.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and
'/>"/>

SOURCE Quanticel Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... BEACH GARDENS, Fla. , Jan. 15, 2014  In an unprecedented ... difficile and TB in ambulances and other transport vehicles, an advanced ... used by rescue personnel for the first time. ... in contact with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... The Cadence Fitness & Health Center has been ... Fitness Association, a non-profit organization assisting medically integrated health ... Cadence Fitness & Health Center is the only certified ... the Chicagoland area. "The certification means the ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... , Findings Published in Nature Medicine Suggest Broad Implications ... , SOUTH SAN FRANCISCO, Calif., June 15 ... in Nature Medicine, Proteolix,s selective immunoproteasome inhibitor ... models of rheumatoid arthritis in a dose-dependent manner and ...
... Biologic Activity Data Reviewed in End of Phase 2a Meeting ... Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company ... cardiovascular and metabolic disease, announced today that an end of ... was recently held with the U.S. Food and Drug Administration ...
Cached Medicine Technology:Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 2Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
(Date:4/18/2014)... group of scientists from the University of Kentucky ... Aging has found interesting new information in a ... disease (PD). , Published in the journal ... cognitive function in depressed and non-depressed patients with ... used to treat motor symptoms of Parkinson,s disease ...
(Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
(Date:4/18/2014)... Calif. (April 18, 2014) ― A new study in ... weekly patterns in health-related Google searches reveals a recurring ... strategies. , Investigators from San Diego State ... the Monday Campaigns, analyzed "healthy" Google searches (searches that ... "healthy diet") originating in the U.S. from 2005 to ...
(Date:4/17/2014)... Men who show signs of chronic inflammation in non-cancerous ... actually having prostate cancer than those with no inflammation, ... researchers from the Johns Hopkins Kimmel Cancer Center. , ... stronger for men with so-called high-grade prostate cancer ... indicating the presence of the most aggressive and ...
(Date:4/17/2014)... published today in PLOS Pathogens , children who ... common can mount an immune response to infection with ... bouts of high fever and illness and partially control ... findings may help researchers develop future interventions that prevent ... , Each year, approximately 200 million cases of malaria ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2
... BROOK, Ill., July 7 The University HealthSystem,Consortium (UHC), ... of Chief Learning Officer. Dr. Pingleton has more than ... to UHC from The,University of Kansas School of Medicine ... Chair of Internal Medicine. From 2007-2008, Dr.,Pingleton was the ...
... commonly associated with Type 2 diabetes also have much greater ... to research to be presented today (Tuesday 8 July 2008). ... key collaborator on an international study which will today be ... The study found that women who were overweight or had ...
... pressure, studies show , , MONDAY, July 7 (HealthDay News) -- ... and vegetable cooking oils appear to help prevent heart attacks, ... keep blood pressure low, two international research teams report. , ... omega-3 fatty acids reduced the risk of heart attack by ...
... most trusted and,accessible health care providers, pharmacists play ... more than 80 million recommendations to their,patients every ... In fact, a recent survey, conducted by Harris ... Education, found that,most Americans (80%) would purchase a ...
... fight to protect Pennsylvania families ... from inadequate regulations, ... and advocates for the elderly and the disabled is pushing,for ... The Pennsylvania Assisted Living Consumer Alliance (PALCA) formed this,year to ...
... Alterations in a molecular brain pathway activated by marijuana ... to a report in the July issue of ... journals. , Expression of the cannabinoid 1 receptor (CB1R), ... of marijuana, is significantly reduced in the brains of ...
Cached Medicine News:Health News:University HealthSystem Consortium Names Susan K. Pingleton, MD, as Its Chief Learning Officer 2Health News:Omega-3, Some Omega-6 Fatty Acids Boost Cardiovascular Health 2Health News:Omega-3, Some Omega-6 Fatty Acids Boost Cardiovascular Health 3Health News:New Coalition Presses for Quality Standards for Assisted Living Facilities in PA 2Health News:New Coalition Presses for Quality Standards for Assisted Living Facilities in PA 3Health News:New Coalition Presses for Quality Standards for Assisted Living Facilities in PA 4Health News:Schizophrenia linked to dysfunction in molecular brain pathway activated by marijuana 2
Pipetman 8X200 Multichannel Pipette is an eight-channel, fully adjustable, air-displacement pipette having a useful volume range from 20 L to 200 L. Robustwith the usual Gilson qualities this pipette...
Inquire...
... is precision, ergonomics, and value! , ... soft non-slip, contoured handle , Finer control ... action , Stress-free tip ejection with long, ... easy decontamination and sterilization without the need ...
... Lightest Pipettor , , The Shortyavailable with ... of how our face-to-face relationship with the scientific ... that make pipetting easier and more effective., ... pipettors., Gets you closer to the working ...
Medicine Products: